Your session is about to expire
← Back to Search
TAK-981 + Pembrolizumab for Solid Cancers
Study Summary
This trial is testing a new combination treatment of TAK-981 with pembrolizumab to see if it is safe and effective in treating people with advanced or metastatic solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am taking or need to take strong medication that affects liver enzymes.I had major surgery less than 14 days ago and haven't fully recovered.I am currently being treated for an infection.I stopped an immune therapy due to side effects.My cancer is advanced and cannot be removed by surgery.I haven't had serious heart issues in the last 6 months.I have had lung inflammation or lung disease that needed steroids.I have recovered from side effects of my previous treatment, or they are stable.My organs are functioning well.I have lung inflammation not caused by an infection.I am fully active or restricted in physically strenuous activity but can do light work.I have untreated or uncontrollable brain cancer spread.I have not had another type of cancer in the last 3 years.I take more than 10 mg/day of prednisone or similar drugs for an autoimmune disease.
- Group 1: Dose Expansion Phase: Cohort F: CPI Refractory Squamous or Nonsquamous NSCLC
- Group 2: Dose Escalation: TAK-981 + Pembrolizumab (Fixed Dose)
- Group 3: Dose Expansion Phase: Cohort D: Cutaneous Melanoma
- Group 4: Dose Expansion Phase: Cohort E: Squamous NSCLC
- Group 5: Dose Expansion Phase: Cohort C: MSS-CRC
- Group 6: Dose Expansion Phase: Cohort A: Non-squamous NSCLC
- Group 7: Dose Expansion Phase: Cohort B: Cervical Cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people needed for this research project?
"That is correct. The information available on clinicaltrials.gov does show that this particular trial is still looking for volunteers. This specific trial was first announced on 8/17/2020 and the most recent update was 9/13/2022. So far, 11 different locations have been used to recruit the 265 participants needed for the study."
What is the extent of research on TAK-981?
"TAK-981 is currently being researched in 1003 clinical trials, 122 of which are in the final stage. Most of these studies taking place in Houston, Texas; however, there are 36125 research sites for this medication globally."
How many different places are conducting this trial?
"There are 11 sites available for this clinical trial, which include the Providence Cancer Institute, Franz Clinic in Portland, Honor Health Research Institute in Scottsdale, and Henry Ford Hospital in Detroit."
What is the maximum sample size for this research project?
"That is accurate. The clinical trial was originally posted on 8/17/2020, as the website clinicaltrials.gov attests, and is currently seeking patients. 11 different hospitals or medical facilities are participating in this study which will enroll 265 individuals in total."
Share this study with friends
Copy Link
Messenger